KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short term Debt (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Short term Debt for 7 consecutive years, with $380.0 million as the latest value for Q4 2025.

  • Quarterly Short term Debt fell 61.92% to $380.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $380.0 million through Dec 2025, down 61.92% year-over-year, with the annual reading at $380.0 million for FY2025, 61.92% down from the prior year.
  • Short term Debt hit $380.0 million in Q4 2025 for Royalty Pharma, roughly flat from $380.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $999.4 million in Q2 2025 to a low of $98.6 million in Q1 2023.
  • Historically, Short term Debt has averaged $533.1 million across 5 years, with a median of $380.0 million in 2025.
  • Biggest five-year swings in Short term Debt: surged 824.19% in 2022 and later tumbled 61.92% in 2025.
  • Year by year, Short term Debt stood at $107.9 million in 2021, then soared by 824.19% to $997.5 million in 2022, then increased by 0.19% to $999.4 million in 2023, then fell by 0.16% to $997.8 million in 2024, then crashed by 61.92% to $380.0 million in 2025.
  • Business Quant data shows Short term Debt for RPRX at $380.0 million in Q4 2025, $380.0 million in Q3 2025, and $999.4 million in Q2 2025.